{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000071","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-08-05T11:32:20+00:00","discovered_at":"2026-08-05T11:35:03.469355+00:00","generated_at":"2026-08-05T11:35:08.972644+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Summit expands ivonescimab into bladder cancer with Phase II/III HARMONi-GU1 trial","bullets":["Ivonescimab plus enfortumab vedotin (EV) vs pembrolizumab plus EV as 1L therapy for locally advanced/metastatic urothelial carcinoma.","Phase II/III trial aims to enroll ~800 patients; Phase III endpoints are PFS and OS.","Global site activations planned to begin by Q4 2026.","Ivonescimab now in 16 Phase III trials across multiple tumor types including lung, colorectal, and bladder."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000071","json":"https://secwatch.observer/filing/0001599298-26-000071.json","markdown":"https://secwatch.observer/filing/0001599298-26-000071.md","text":"https://secwatch.observer/filing/0001599298-26-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/0001599298-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/smmt-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:35:08.972644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}